Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq: HUMA) will feature its regenerative medicine technology in three presentations at the American Heart Association Scientific Sessions 2026.
The conference runs November 6–9 at McCormick Place in Chicago. Founder and CEO Laura Niklason will give an invited talk on vascular regeneration on November 7. Two other presentations will cover the first-in-human Phase 2a study design and preclinical results in pig and sheep models for the company’s coronary tissue engineered vessel, intended for coronary artery bypass grafting. Those presentations are scheduled for November 7 and November 8, respectively. The coronary vessel remains investigational and is not approved for sale by the FDA or any other regulatory agency.
Humacyte (HUMA) will release its third-quarter 2026 financial results and provide a business update on November 10, 2026. The results will cover the three months and nine months ended September 30, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the corporate and financial update.
Humacyte (Nasdaq: HUMA) received a new U.S. patent covering aspects of Symvess manufacturing, sterilization, storage and shipping, with protection into 2043.
U.S. Patent No. 12,742,144 also covers other bioengineered human tissues and complements existing patents and applications covering product design, composition and manufacturing methods. Symvess is an acellular tissue engineered vessel, a bioengineered blood vessel, that received FDA approval for extremity vascular trauma in December 2024. Humacyte plans to submit a supplemental biologics license application in 2026 seeking to add dialysis access as a second approved indication.
Humacyte (HUMA) reported that its Phase 3 V012 trial met the primary endpoint comparing bioengineered vessels with fistulas in female hemodialysis patients. The prespecified interim analysis covered the first 80 patients; enrollment stopped after the endpoint was met. Women receiving the acellular tissue engineered vessel (ATEV) averaged 220 catheter-free days in the first year, versus 129 with a surgically created arteriovenous fistula. Median time to functional dialysis access was 1.7 months versus 5.3 months.
Safety was comparable between groups. Dialysis access infections occurred at approximately 6 versus 23 per 100 patient-years, with no vessel-related infections in the ATEV group or spontaneous ruptures in either group. Humacyte targets an FDA application this quarter to expand the Symvess label to hemodialysis access, supported by V012 and two previously completed Phase 3 trials.
Humacyte (HUMA) reported a 44% third-quarter increase in hospitals that have ordered Symvess, its FDA-approved vessel for vascular trauma. The total rose from 34 hospitals at the end of the second quarter to 49 as of September 30, 2026. New hospital ordering activity increased sequentially each month of the third quarter.
Humacyte said the adoption trend shows potential to surpass its goal of adding 20 new hospitals by year-end and expects substantial growth through the remainder of 2026. Its revised commercial strategy began in the second quarter. Symvess is approved for adults with extremity arterial injury who need urgent restoration of blood flow to avoid imminent limb loss and cannot receive a graft made from their own vein. Further commercial updates are planned for the third-quarter earnings call.
Humacyte (HUMA) will present interim Phase 3 V012 trial results at an ASN Kidney Week late-breaking session on October 22, 2026. The randomized trial compares its acellular tissue engineered vessel (ATEV), a bioengineered blood vessel, with an arteriovenous fistula, a connection made from a patient's own blood vessels, for hemodialysis access in women with end-stage kidney disease. Prabir Roy-Chaudhury of the University of North Carolina at Chapel Hill will present the findings in Denver.
V012 results and two previously completed Phase 3 hemodialysis-access trials form the clinical foundation for a planned supplemental application to expand the Symvess label to include this use. Humacyte targets submission to the FDA this quarter. ATEV remains investigational for hemodialysis access; its existing FDA approval covers extremity vascular trauma.
Humacyte (HUMA) appointed Scott Coward and Paul Kuznik to its board of directors as it prepares a dialysis-access launch.
Coward joined the Audit Committee. He previously held executive and board roles at Exact Sciences, where he led the integration of Genomic Health following its acquisition. Kuznik joined the Commercial Committee. He previously led Bolton Medical and held U.S. and North American leadership roles at Terumo Aortic. Humacyte is expanding its ongoing Symvess launch and said it plans a U.S. commercial launch of its acellular tissue engineered vessel, or ATEV, for dialysis access. That use remains investigational and is not approved for sale by the FDA or any other regulator. ATEV is approved for extremity vascular trauma.
Humacyte (HUMA)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 16, 2026, at 11:00 a.m. Eastern Time.Management will also be available for one-on-one investor meetings during the event at the Lotte New York Palace Hotel. A live webcast of the presentation and a replay for a limited time will be accessible through the Events & Presentations section of Humacyte’s website.
Humacyte is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues. Its acellular tissue engineered vessel (ATEV) for vascular trauma received FDA Biologics License Application approval in December 2024 and holds priority designation from the U.S. Secretary of Defense. Additional ATEV programs are in late-stage clinical trials for arteriovenous access in hemodialysis and peripheral artery disease, and in preclinical development for several cardiovascular and metabolic indications.
Humacyte (HUMA) received FDA authorization to extend the refrigerated expiration dating of Symvess (acellular tissue engineered vessel, ATEV) from 18 months to 36 months when stored at 2°C to 8°C (36°F to 46°F).
The longer shelf life is supported by additional stability data showing Symvess continues to meet all established quality specifications throughout the 36‑month period under approved storage conditions. The company states that the extended dating may help hospitals maintain Symvess inventory for urgent vascular repairs, simplify inventory planning, and reduce product waste while keeping storage requirements and approved clinical use unchanged.
Symvess remains FDA‑approved only as a vascular conduit for adults with extremity arterial injury requiring urgent revascularization when an autologous vein graft is not feasible; other uses are investigational.
Humacyte (Nasdaq: HUMA) plans to file a supplemental Biologics License Application (BLA) with the FDA in November 2026 to seek a second indication for its acellular tissue engineered vessel (ATEV) in dialysis access, following its December 2024 FDA approval for vascular trauma.
According to Humacyte, the filing will be supported by three Phase 3 studies (V012, V007, V006). In the V012 dialysis access study in women, ATEV recipients had an average of three more months without a dialysis catheter than those receiving arteriovenous fistula, the current standard of care. The ATEV remains investigational for all uses other than extremity vascular trauma.